Human CXCR5⁺ PD-1⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies.

ABSTRACT: Immune checkpoint blockade (ICB) has revolutionized cancer therapy, but varying response rates illustrate the need for biomarkers of response. Studies in mice have identified a subset of CD8 T cells that is essential for response to PD-1 ICB. These CD8 T cells co-express CXCR5, PD-1 and Tcf1, and provide effector T cells upon PD-1 ICB. It is unknown whether similar T cells play a role in PD-1 ICB in humans. We studied human peripheral blood and lymph nodes (LNs) for the frequency, phenotype, and functionality of CXCR5⁺ PD-1⁺ CD8 T cells. We find that CXCR5⁺ PD-1⁺ CD8 T cells are memory-like cells, express Tcf1, and lack expression of effector molecules. CXCR5⁺ PD-1⁺ CD8 T cells produce cytokines upon stimulation, but have limited proliferative capacity. We studied patients with hematologic malignancies with varying response rates to PD-1 ICB. Specifically in chronic lymphocytic leukemia, in which PD-1 ICB does not induce clinical responses, CXCR5⁺ PD-1⁺ CD8 T cells show loss of the memory phenotype and increased effector differentiation. In conclusion, we identified CXCR5⁺ PD-1⁺ CD8 T cells in human peripheral blood and LN, which could play a similar role during PD-1 ICB. Future studies should analyze CXCR5⁺ PD-1⁺ CD8 T cells during PD-1 ICB and their importance for therapeutic response.

SUBMITTER: Hofland T 

PROVIDER: S-EPMC7984320 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature